Persistence of Immune Response After Vaccination With MCC

A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00310687

Enrollment

1244

Registered

2006-04-04

Start date

2004-10-31

Completion date

2005-12-31

Last updated

2014-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of Meningococcal Infection

Keywords

Prevention of Meningococcal Meningitis, vaccines, conjugate, immunology, antibody persistence

Brief summary

Persistence of Immune response after vaccination with MCC

Interventions

PROCEDUREBLOOD DRAW

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

11 Years to 20 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy adolescents vaccinated with Meningococcal C Conjugate vaccine

Exclusion criteria

* ascertained or suspected disease caused by N. meningitidis * household contact with individuals with proven N. meningitidis serogroup C infection * significant acute or chronic infections * any other serious disease

Design outcomes

Primary

Measure	Time frame
persistence of memory response to N. meningitidis serogroup C as measured by serum bactericidal activity at one year after either a challenge with 1/5 of a dose of Meningococcal A/C Polysaccharide vaccine or a booster dose of MenC Vaccine.	—

Secondary

Measure	Time frame
Evaluation and comparison of the persistence of antibodies against N. meningitidis serogroup C as measured by hBCA	—
Evaluation of the immunological response (ELISA) to N. meningitidis serogroup C	—

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026